P. Isidori

发表

N-Acetylcysteine Reduces the Exacerbation Rate in Patients with Moderate to Severe COPD

C. Sanguinetti, R. Pela, A. Calcagni, 1999, Respiration.

A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV‐E) or teniposide (CAV‐T), followed by recombinant interferon‐α maintenance therapy or observation, in small cell lung carcinoma patients with complete responses

R. Cellerino, F. Graziano, D. Mari, 1997, Cancer.

Teniposide as single drug therapy for elderly patients affected by small cell lung cancer.

R. Cellerino, G. Cetto, F. Pasini, 1992, European journal of cancer.

Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.

S. Gasparini, F. Graziano, D. Mari, 1994, Anticancer research.

A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer.

F. Guidi, R. Cellerino, G. Fatati, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin‐C) regimen: A phase II study

R. Cellerino, A. Fedeli, F. Graziano, 1996, Cancer.

Lonidamine, chemotherapy (cisplatin and etoposide) and chemotherapy plus lonidamine vs the best supportive care in the treatment of advanced non small cell lung cancer (NSCLC). Preliminary results of a randomized study

S. Gasparini, P. Isidori, B. Farabollini, 1991 .

Experience with Intrapleural Natural Beta Interferon in the Treatment of Malignant Pleural Effusions

S. Cascinu, S. Fedeli, A. Fedeli, 1991, Tumori.

Induction chemo-radiotherapy and maintenance alternating chemotherapy for small cell lung cancer.

C. Dazzi, F. Guidi, R. Cellerino, 1990, Acta oncologica.

Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C

R. Cellerino, F. Graziano, P. Isidori, 2004, Cancer Chemotherapy and Pharmacology.

Phase II Trial with Alternating Two Drug Schedules, CAP/MEC', For Advanced (Stage III Mo/Ml) Non-Small-Cell Lung Cancer

F. Guidi, R. Cellerino, G. Fatati, 1989, Tumori.

Non small cell lung cancer (NSCLC). A prospective randomized trial with alternating chemotherapy CEP/MEC' versus no treatment.

F. Guidi, E. Porfiri, R. Cellerino, 1988, European journal of cancer & clinical oncology.